In terms of morbidity and mortality, cardiovascular illnesses are the main cause of death worldwide. Half of all noncommunicable diseases on the earth are caused by them. Due to the steadily rising mortality rates from circulatory diseases in Kazakhstan, our region was identified as having a high cardiovascular risk in 2021 when the updated Score 2 (Systematic COronary Risk Evaluation) scale was developed. There has been a recent increase in this pathology's prevalence among younger people (up to 44 years). In this regard, a large number of scholars are engaged in active research into the variables that affect the onset of coronary heart disease in this population, particularly its acute forms, which frequently mark the onset of the disease in this age group. The research of international experts supports the impact of classic risk factors such arterial hypertension, smoking, dyslipidemia, diabetes mellitus, inactivity, and loaded anamnesis on the early development of atherosclerosis. The Fourth Universal Definition distinguishes five different forms of myocardial infarction, and if the first type is directly linked to atherogenesis, the second type develops as a result of ischemia imbalance in the absence of coronary artery obstructive lesions. There are currently no definite, widely acknowledged standards for the identification and management of type 2 myocardial infarction. Thereby there was a need to research the impact of additional risk factors, such as subclinical systemic inflammation, genetic polymorphism of genes involved in lipid metabolism, thrombosis, and responsible for the development of endothelial dysfunction, given the differences in the pathogenetic mechanisms of different types of myocardial infarction. It's still up for debate whether comorbidity has any impact on the frequency of early cardiovascular events in the population of young individuals. Aim is to study international approach in an assessment of risk factors of the development of myocardial infarction at young population. The review used content analysis on the research topic, national guidelines, WHO recommendations. The electronic databases Pubmed, eLibrary from 1999 to 2022 were used as sources of information. The search was conducted on the keywords «myocardial infarction», «infarction in young», «risk factors» and MeSH terms «myocardial infarction/etiology», «myocardial infarction/young», «myocardial infarction/risk factors». Of the 50 sources found, 37 corresponded to the research request. This field of scientific study is one of the most important today because of the prevalence of formation and poor prognosis of non-atherothrombogenic myocardial infarctions, compared with type 1 infarcts. Numerous foreign and domestic authors have been motivated to look for new markers of the early onset of coronary heart disease, develop adequate risk stratification algorithms, and create efficient primary and secondary prevention strategies at the level of primary healthcare and hospitals as a result of the high mortality and disability rates in this age group that are a significant economic and social problem.
Download full-text PDF |
Source |
---|
J Cardiothorac Surg
January 2025
The First Hospital of Lanzhou University, Lanzhou, China.
Background: This article aims to use high-throughput sequencing to identify miRNAs associated with ferroptosis in myocardial ischemia-reperfusion injury, select a target miRNA, and investigate its role in H9C2 cells hypoxia-reoxygenation injury.
Methods: SD rats and H9C2 cells were used as subjects. ELISA kits quantified MDA, SOD, GSH, LDH, and ferritin levels.
Int J Obes (Lond)
January 2025
Department of Cardiology, Peking University First Hospital, Beijing, China.
Background: Several studies have attempted to demonstrate the associations between body mass index (BMI) in early age and cardiovascular diseases (CVDs). However, their findings were inconsistent and inconclusive, indicating the need for further investigation.
Methods: We conducted a systematic review and meta-analysis of studies focusing on BMI in early age (age from 2 to 22) in relation to CVDs in adulthood, including coronary artery disease (CHD), ischemic and hemorrhagic stroke, myocardial infarction and heart failure.
Nat Cardiovasc Res
January 2025
Department of Pharmacy at the Second Affiliated Hospital, and Department of Pharmacology at College of Pharmacy (The Key Laboratory of Cardiovascular Research, Ministry of Education; National Key Laboratory of Frigid Zone Cardiovascular Diseases), Harbin Medical University, Harbin, China.
Targeting the cardiomyocyte cell cycle is a promising strategy for heart repair following injury. Here, we identify a cardiac-regeneration-associated PIWI-interacting RNA (CRAPIR) as a regulator of cardiomyocyte proliferation. Genetic ablation or antagomir-mediated knockdown of CRAPIR in mice impairs cardiomyocyte proliferation and reduces heart regenerative potential.
View Article and Find Full Text PDFJ Cardiothorac Vasc Anesth
December 2024
Kore University, Enna, Italy and Centro Cuore GB Morgagni, Catania, Italy.
Objectives: The benefit of combining multiple mechanical circulatory support (MCS) systems in patients with cardiogenic shock (CS) is debated. This review examines patient characteristics across studies to identify differences and assesses if patients with a higher-risk clinical profile receive Impella unloading.
Design: A systematic review and meta-analysis was conducted to examine if there were significant differences in baseline clinical parameters among patients receiving MCS in addition to venoarterial extracorporeal membrane oxygenation (VA ECMO).
JACC Cardiovasc Interv
January 2025
Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA. Electronic address:
Background: The risk-benefit ratio of the Absorb bioresorbable vascular scaffold (BVS) may vary before and after 3 years, the time point of complete bioresorption of the poly-L-lactic acid scaffold.
Objectives: The aim of this study was to determine the time-varying outcomes of the Absorb BVS compared with cobalt-chromium everolimus-eluting stents (EES) from a large individual-patient-data pooled analysis of randomized trials.
Methods: The individual patient data from 5 trials that randomized 5,988 patients undergoing percutaneous coronary intervention to the Absorb BVS vs EES with 5-year follow-up were pooled.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!